Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study.

Investig Clin Urol · 2020 · PMC7606124 · PMID 32985144

Europe PMC DOI

hedged sentence

0.0610

closest p · 1.2× alpha

0.0610

boldest claim

The sentences

did not reach statistical significancep=0.061so close (0.05 < p ≤ 0.1)

In the rechallenge setting, PFS was longer in patients with >24 months of interval (9.4 months) than in those with interval ≤24 months (3.3 months); however, the difference did not reach statistical significance (hazard ratio [HR], 0.55; 95% CI, 0.20 to 1.51; p=0.061).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.